CancerDrs Find care

Prostate Cancer clinical trials in New Jersey

25 actively recruiting prostate cancer trials at 34 sites across New Jersey.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in New Jersey:
  • Jersey City Medical Center — Jersey City, New Jersey
  • Saint Barnabas Medical Center — Livingston, New Jersey
  • Monmouth Medical Center — Long Branch, New Jersey
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
  • Rutgers New Jersey Medical School — Newark, New Jersey
Phase 3 Recruiting Academic/Other

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…

Sponsor: NRG Oncology
NCT ID: NCT04134260
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Cooper Hospital University Medical Center — Camden, New Jersey
  • Saint Barnabas Medical Center — Livingston, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
  • Sidney Kimmel Cancer Center Washington Township — Sewell, New Jersey
Phase 3 Recruiting Industry

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Sponsor: AstraZeneca
NCT ID: NCT06120491
Sites in New Jersey:
  • Research Site — Belleville, New Jersey
  • Research Site — Brick, New Jersey
  • Research Site — Camden, New Jersey
  • Research Site — East Brunswick, New Jersey
  • Research Site — Voorhees Township, New Jersey
Phase 3 Recruiting Industry

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in New Jersey:
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 2, Phase 3 Recruiting Industry

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in New Jersey:
  • New Jersey Urology LLC — Voorhees Township, New Jersey
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Industry

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in New Jersey:
  • Hackensack University Medical Center — Hackensack, New Jersey
Phase 1, Phase 2 Recruiting Academic/Other

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant pr…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06457919
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other

A Study of Tarlatamab for People With Prostate Cancer

The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back afte…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07111507
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researche…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06347705
Sites in New Jersey:
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Industry

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…

Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07332000
Sites in New Jersey:
  • Summit Health — Saddle Brook, New Jersey
Phase 2 Recruiting Academic/Other

A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

The researchers are doing this study to find out if stereotactic body radiation therapy (SBRT) without androgen deprivation therapy (ADT) is an effective treatment approach for people with unfavorable intermediate-risk prostate. The resear…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05169970
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people w…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07335796
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Industry

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating pati…

Sponsor: Eikon Therapeutics
NCT ID: NCT07262619
Sites in New Jersey:
  • Morristown Medical Center — Morristown, New Jersey
Phase 2 Recruiting Academic/Other

Ultralow Dose PET Imaging for PSMA Expression

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan dur…

Sponsor: Akiva Mintz
NCT ID: NCT06904313
Sites in New Jersey:
  • Nuclear Imaging Institute — Englewood, New Jersey
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in New Jersey:
  • Exelixis Clinical Site #88 — East Brunswick, New Jersey
  • Exelixis Clinical Site #105 — Hackensack, New Jersey
Phase 1 Recruiting Industry

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…

Sponsor: Pfizer
NCT ID: NCT03460977
Sites in New Jersey:
  • Hackensack University Medical Center — Hackensack, New Jersey
  • John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in New Jersey:
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in New Jersey:
  • Englewood Hospital and Medical Center — Englewood, New Jersey
  • CentraState Medical Center — Freehold, New Jersey
  • Hackettstown Medical Center — Hackettstown, New Jersey
  • Morristown Medical Center — Morristown, New Jersey
  • Inspira Medical Center Mullica Hill — Mullica Hill, New Jersey
Recruiting Academic/Other

RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most …

Sponsor: The Radiosurgery Society
NCT ID: NCT01885299
Sites in New Jersey:
  • AtlantiCare Regional Medical Center and AtlantiCare Cancer Care Institute — Egg Harbor, New Jersey
  • Riverview Medical Center — Red Bank, New Jersey
  • NJ Cyberknife at Community Medical Center — Toms River, New Jersey
NA Recruiting Academic/Other

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT00588185
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Consent Only) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Consent only) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Consent Only) — Montvale, New Jersey
NA Recruiting Academic/Other

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care. MSK's goal is to make getting cancer care easier by cutting down the need to make in-person visits to MSK. MSK is trying to do…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06954337
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
NA Recruiting Industry

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiatio…

Sponsor: Palette Life Sciences, Inc.
NCT ID: NCT06496256
Sites in New Jersey:
  • Summit Health — Clifton, New Jersey

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20